Clinical issues in use of atypical antipsychotics for depressed patients.

Abstract:

:Major depressive disorder (MDD) is a chronic, recurrent mental disease that causes serious disability. Because currently available antidepressants have limited efficacy with respect to response and remission in patients with MDD, clinicians must choose the best available treatment interventions for patients who do not respond to initial antidepressant treatment. The existing literature demonstrates that augmentation with atypical antipsychotics (AAs) shows higher response and remission rates compared with antidepressant monotherapy, but is associated with more withdrawals due to adverse events. In this paper, specific clinical issues in the use of AA augmentation for patients with MDD are briefly discussed. Given the limited information and clinical knowledge on the proper and effective use of AAs for MDD, future research should focus on practical clinical issues that can be commonly seen in routine practice but have not been addressed yet. This is because the use of AAs is likely to expand as there is good evidence for their effectiveness and tolerability as augmentation therapy for patients with MDD.

journal_name

CNS Drugs

journal_title

CNS drugs

authors

Pae CU,Patkar AA

doi

10.1007/s40263-012-0032-z

subject

Has Abstract

pub_date

2013-05-01 00:00:00

pages

S39-45

eissn

1172-7047

issn

1179-1934

journal_volume

27 Suppl 1

pub_type

杂志文章,评审
  • Rapidity of CNS Effect on Photoparoxysmal Response for Brivaracetam vs. Levetiracetam: A Randomized, Double-blind, Crossover Trial in Photosensitive Epilepsy Patients.

    abstract:INTRODUCTION:Both levetiracetam (LEV) and brivaracetam (BRV) eliminate the electroencephalogram photoparoxysmal response (PPR) in the human phase IIa photosensitivity model of epilepsy. The physiochemical properties of BRV differ from those of LEV, having higher potency and lipophilicity plus 10- to 15-fold greater aff...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-020-00761-1

    authors: Reed RC,Rosenfeld WE,Lippmann SM,Eijkemans RMJC,Kasteleijn-Nolst Trenité DGA

    更新日期:2020-10-01 00:00:00

  • Maternal Anti-Fetal Brain IgG Autoantibodies and Autism Spectrum Disorder: Current Knowledge and its Implications for Potential Therapeutics.

    abstract::Several studies have found a correlation between the presence of circulating maternal autoantibodies and neuronal dysfunction in the neonate. Specifically, maternal anti-brain autoantibodies, which may access the fetal compartment during gestation, have been identified as one risk factor for developing autism spectrum...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-015-0279-2

    authors: Fox-Edmiston E,Van de Water J

    更新日期:2015-09-01 00:00:00

  • Clinically important drug interactions with zopiclone, zolpidem and zaleplon.

    abstract::Insomnia, an inability to initiate or maintain sleep, affects approximately one-third of the American population. Conventional benzodiazepines, such as triazolam and midazolam, were the treatment of choice for short-term insomnia for many years but are associated with adverse effects such as rebound insomnia, withdraw...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200317070-00004

    authors: Hesse LM,von Moltke LL,Greenblatt DJ

    更新日期:2003-01-01 00:00:00

  • Overview of the therapeutic management of insomnia with zolpidem.

    abstract::Benzodiazepine hypnotic agents were the mainstream pharmacotherapy for insomnia from the 1960s to the 1980s, but their safety profile proved to be not quite as perfect as originally expected with regard to daytime performance and cognition, and above all the risk of dependence. These risks are substantially diminished...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200418001-00005

    authors: Lee YJ

    更新日期:2004-01-01 00:00:00

  • Pharmacotherapy of malignant astrocytomas of children and adults: current strategies and future trends.

    abstract::This article reviews the conceptual progression in the pharmacological therapy of malignant astrocytoma (MA) over the past decade, and its future trends. It is a selective rather than an exhaustive inventory of literature citations. The experience of the Brain Tumour Cooperative Group (BTCG) and earlier phase III tria...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200115090-00005

    authors: Jennings MT,Iyengar S

    更新日期:2001-01-01 00:00:00

  • Does pharmacological treatment of ADHD in adults enhance parenting performance? Results of a double-blind randomized trial.

    abstract:OBJECTIVE:This study examines the effects of parental lisdexamfetamine (LDX) treatment on parent-child interactions. METHODS:Participants were 30 parents (27% were male) and their children aged 5-12 years, both diagnosed with DSM-IV attention-deficit/hyperactivity disorder (ADHD). Optimal LDX dose (30, 50, or 70 mg/da...

    journal_title:CNS drugs

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s40263-014-0165-3

    authors: Waxmonsky JG,Waschbusch DA,Babinski DE,Humphrey HH,Alfonso A,Crum KI,Bernstein M,Slavec J,Augustus JN,Pelham WE

    更新日期:2014-07-01 00:00:00

  • Biological markers of age-related memory deficits: treatment of senescent physiology.

    abstract::In humans, age-related memory impairments begin in mid-life and cognitive weakening continues with advancing age. An important aspect of defining memory decline is the distinction between dementia as a result of neurological diseases, such as Alzheimer's disease, and memory loss not specifically associated with diseas...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200620020-00006

    authors: Foster TC

    更新日期:2006-01-01 00:00:00

  • Drug Repurposing in Parkinson's Disease.

    abstract::The development of an intervention to slow or halt disease progression remains the greatest unmet therapeutic need in Parkinson's disease. Given the number of failures of various novel interventions in disease-modifying clinical trials in combination with the ever-increasing costs and lengthy processes for drug develo...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-018-0548-y

    authors: Athauda D,Foltynie T

    更新日期:2018-08-01 00:00:00

  • Methylene Blue in the Treatment of Neuropsychiatric Disorders.

    abstract::Methylene blue is a long-established drug with complex pharmacology and multiple clinical indications. Its diverse mechanisms of action are most likely responsible for the large variety of its clinical effects. Of interest to psychiatrists, methylene blue has antidepressant, anxiolytic, and neuroprotective properties ...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-019-00641-3

    authors: Alda M

    更新日期:2019-08-01 00:00:00

  • Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination.

    abstract::The coronavirus 2019 (COVID-19) pandemic is expected to linger. Decisions regarding initiation or continuation of disease-modifying therapy for multiple sclerosis have to consider the potential relevance to the pandemic. Understanding the mechanism of action and the possible idiosyncratic effects of each therapeutic a...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-020-00756-y

    authors: Zheng C,Kar I,Chen CK,Sau C,Woodson S,Serra A,Abboud H

    更新日期:2020-09-01 00:00:00

  • Treatment Options for Narcolepsy.

    abstract::Narcolepsy type 1 and narcolepsy type 2 are central disorders of hypersomnolence. Narcolepsy type 1 is characterized by excessive daytime sleepiness and cataplexy and is associated with hypocretin-1 deficiency. On the other hand, in narcolepsy type 2, cerebrospinal fluid hypocretin-1 levels are normal and cataplexy ab...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-016-0337-4

    authors: Barateau L,Lopez R,Dauvilliers Y

    更新日期:2016-05-01 00:00:00

  • Cardiovascular effects and risk of syncope related to donepezil in patients with Alzheimer's disease.

    abstract:BACKGROUND:When otherwise unexplained, syncope in patients with Alzheimer's disease may be attributed to bradycardia caused by cholinesterase inhibitors. We studied prospectively the clinical events and cardiovascular changes occurring during treatment with donepezil in patients with Alzheimer's disease. METHODS:Conse...

    journal_title:CNS drugs

    pub_type: 临床试验,杂志文章

    doi:10.2165/00023210-200620050-00005

    authors: Bordier P,Garrigue S,Lanusse S,Margaine J,Robert F,Gencel L,Lafitte A

    更新日期:2006-01-01 00:00:00

  • A single-dose pilot trial of intranasal rapid-acting insulin in apolipoprotein E4 carriers with mild-moderate Alzheimer's disease.

    abstract:INTRODUCTION:Intranasal (IN) insulin acutely improves verbal memory in mild cognitive impairment (MCI)/Alzheimer's disease (AD), but its therapeutic effects may be attenuated in apolipoprotein E4 (ApoE4) carriers. Furthermore, rapid-acting (RA) insulins may have superior therapeutic effects compared with regular insuli...

    journal_title:CNS drugs

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s40263-014-0214-y

    authors: Rosenbloom MH,Barclay TR,Pyle M,Owens BL,Cagan AB,Anderson CP,Frey WH 2nd,Hanson LR

    更新日期:2014-12-01 00:00:00

  • Factors associated with seizure recurrence in epilepsy patients treated with antiepileptic monotherapy: A retrospective observational cohort study using US administrative insurance claims.

    abstract:BACKGROUND:Few studies examine predictors of seizures in medically treated patients with epilepsy receiving antiepileptic monotherapy using a large patient population. OBJECTIVE:Our objective was to identify clinical, medication, and demographic factors associated with seizure recurrence in medically treated patients ...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-014-0191-1

    authors: Shcherbakova N,Rascati K,Brown C,Lawson K,Novak S,Richards KM,Yoder L

    更新日期:2014-11-01 00:00:00

  • Evaluation of serum levels of chemokines during interferon-β treatment in multiple sclerosis patients: a 1-year, observational cohort study.

    abstract:BACKGROUND:The molecules that provide access to activated T cells in the CNS, including chemokines, have been considered to be a crucial step in the pathogenesis of multiple sclerosis (MS). AIMS:In this study, we investigated serial serum chemokine levels in patients with relapsing-remitting MS over 1 year and the ass...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.2165/11595060-000000000-00000

    authors: Comini-Frota ER,Teixeira AL,Angelo JP,Andrade MV,Brum DG,Kaimen-Maciel DR,Foss NT,Donadi EA

    更新日期:2011-11-01 00:00:00

  • Fatalities associated with therapeutic use and overdose of atypical antipsychotics.

    abstract::Since 1989, several novel antipsychotic drugs have become available for use including clozapine, risperidone, olanzapine, quetiapine and ziprasidone. These agents represent a substantial improvement in the treatment of schizophrenia and related disorders and are considered to have a favourable adverse effect profile r...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200317050-00002

    authors: Trenton A,Currier G,Zwemer F

    更新日期:2003-01-01 00:00:00

  • Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders.

    abstract::The kynurenine pathway constitutes the main route of tryptophan degradation and generates the production of several neuroactive compounds; quinolinic acid is an excitotoxic NMDA receptor agonist, 3-hydroxykynurenine is a free-radical generator and kynurenic acid (KYNA) is an antagonist at glutamate and nicotinic recep...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200923020-00001

    authors: Erhardt S,Olsson SK,Engberg G

    更新日期:2009-01-01 00:00:00

  • Restoring Function to Dopaminergic Neurons: Progress in the Development of Cell-Based Therapies for Parkinson's Disease.

    abstract::There is escalating interest in cell-based therapies to restore lost dopamine inputs in Parkinson's disease. This is based upon the rationale that implanting dopamine progenitors into the striatum can potentially improve dopamine-responsive motor symptoms. A rich body of data describing clinical trials of previous cel...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-020-00727-3

    authors: Henchcliffe C,Sarva H

    更新日期:2020-06-01 00:00:00

  • Spotlight on oxcarbazepine in epilepsy.

    abstract::Oxcarbazepine (Trileptal, Timox) is structurally related to carbamazepine and has anticonvulsant activity. Studies suggest that the anticonvulsant activity of oxcarbazepine is mediated via the blocking of neuronal ion channels. In patients aged <18 years, the efficacy of oxcarbazepine monotherapy was similar to that o...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.2165/00023210-200418010-00006

    authors: Bang LM,Goa KL

    更新日期:2004-01-01 00:00:00

  • Efficacy of olanzapine and ziprasidone for the treatment of schizophrenia: a systematic review.

    abstract::It is difficult to determine the relative efficacy of atypical antipsychotics for the treatment of schizophrenia, based on the available literature. The purpose of this article is to review and compare the efficacy of two atypical antipsychotics: olanzapine and ziprasidone.This review focused on randomised trials in w...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200519060-00003

    authors: Matza LS,Baker TM,Revicki DA

    更新日期:2005-01-01 00:00:00

  • Pharmacotherapy for Friedreich ataxia.

    abstract::Friedreich ataxia (FA) is a progressive genetic neurological disorder associated with degeneration of the dorsal columns, spinocerebellar tracts and other regions of the nervous system. The disorder results from mutations in the gene referred to as FXN. Almost all mutations are expansions of an intronic GAA repeat in ...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200923030-00003

    authors: Tsou AY,Friedman LS,Wilson RB,Lynch DR

    更新日期:2009-01-01 00:00:00

  • Hypnosedative-induced complex behaviours : incidence, mechanisms and management.

    abstract::A number of news items and case reports describing complex behaviours (e.g. sleep driving, sleep cooking, sleep eating, sleep conversations, sleep sex) associated with the use of hypnosedative medications have recently received considerable attention. Regulatory agencies examining these reports have subsequently issue...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/0023210-200822120-00005

    authors: Dolder CR,Nelson MH

    更新日期:2008-01-01 00:00:00

  • Pharmacokinetics and Clinical Utility of Valproic Acid Administered via Continuous Infusion.

    abstract:INTRODUCTION:Valproic acid is a versatile antiepileptic drug that is often used in the acute care setting. Intravenous valproic acid lends itself well to a continuous infusion as it exhibits a relatively short half-life. We evaluated the pharmacokinetics and clinical efficacy of continuous infusion valproic acid in hos...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-015-0304-5

    authors: Cook AM,Zafar MS,Mathias S,Stewart AM,Albuja AC,Bensalem-Owen M,Kapoor S,Baumann RJ

    更新日期:2016-01-01 00:00:00

  • The Therapeutic Role of Gangliosides in Neurological Disorders.

    abstract::Numerous in vitro and in vivo experimental animal studies have demonstrated that gangliosides, particularly GMI ganglioside (siagoside), may stimulate or accelerate the repair of peripheral and central nervous system neurons after various types of damage. Clinical studies of GMl in peripheral neuropathies and stroke, ...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.2165/00023210-199401030-00006

    authors: Schneider JS

    更新日期:1994-03-01 00:00:00

  • Histamine and betahistine in the treatment of vertigo: elucidation of mechanisms of action.

    abstract::The aim of this review is to provide clinicians with a picture of the mechanisms by which: histamine and histaminergic agonists act on the vestibular system both peripherally and centrally; and histaminergic agonists and antagonists interfere with the recovery process after peripheral vestibular lesion. We have focuse...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200115110-00004

    authors: Lacour M,Sterkers O

    更新日期:2001-01-01 00:00:00

  • Prospects for improving brain function in individuals with Down syndrome.

    abstract::Down syndrome (DS), which results from an extra copy of chromosome 21 (trisomy 21), is the most common genetically defined cause of intellectual disability. Although no pharmacotherapy aimed at counteracting the cognitive and adaptive deficits associated with this genetic disorder has been approved at present, there h...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-013-0089-3

    authors: Costa AC,Scott-McKean JJ

    更新日期:2013-09-01 00:00:00

  • Targeting Infectious Agents as a Therapeutic Strategy in Alzheimer's Disease.

    abstract::Alzheimer's disease (AD) is the most prevalent dementia in the world. Its cause(s) are presently largely unknown. The most common explanation for AD, now, is the amyloid cascade hypothesis, which states that the cause of AD is senile plaque formation by the amyloid β peptide, and the formation of neurofibrillary tangl...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-020-00737-1

    authors: Fülöp T,Munawara U,Larbi A,Desroches M,Rodrigues S,Catanzaro M,Guidolin A,Khalil A,Bernier F,Barron AE,Hirokawa K,Beauregard PB,Dumoulin D,Bellenger JP,Witkowski JM,Frost E

    更新日期:2020-07-01 00:00:00

  • Newly initiated opioid treatment and the risk of fall-related injuries. A nationwide, register-based, case-crossover study in Sweden.

    abstract:BACKGROUND:There is growing epidemiological evidence that opioids may increase the risk of unintentional injuries and it is plausible that the time of initiation is most critical in that respect. Studies on fall-related injuries remain few, limited and mostly focused on specific groups of elderly patients. OBJECTIVE:T...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-013-0038-1

    authors: Söderberg KC,Laflamme L,Möller J

    更新日期:2013-02-01 00:00:00

  • Tocopherol (vitamin E) in Alzheimer's disease and other neurodegenerative disorders.

    abstract::In this article, we review the evidence that tocopherol (vitamin E) may have a role to play in the prevention and treatment of Alzheimer's disease and other neurological diseases. The theoretical rationale for the effectiveness of tocopherol as treatment and/or prevention of Alzheimer's disease is based on its antioxi...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200418120-00005

    authors: Berman K,Brodaty H

    更新日期:2004-01-01 00:00:00

  • Therapeutic options for treatment-resistant depression.

    abstract::Treatment-resistant depression (TRD) presents major challenges for both patients and clinicians. There is no universally accepted definition of TRD, but results from the US National Institute of Mental Health's (NIMH) STAR*D (Sequenced Treatment Alternatives to Relieve Depression) programme indicate that after the fai...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11530280-000000000-00000

    authors: Shelton RC,Osuntokun O,Heinloth AN,Corya SA

    更新日期:2010-02-01 00:00:00